{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Brain+Metastasis",
    "query": {
      "condition": "Melanoma Brain Metastasis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 102,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Brain+Metastasis&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T18:26:38.729Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00002754",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Melanoma (Skin)",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "monoclonal antibody Me1-14 F(ab')2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "1993-02",
      "completion_date": "2001-04",
      "has_results": false,
      "last_update_posted_date": "2013-02-20",
      "last_synced_at": "2026-06-10T18:26:38.729Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002754"
    },
    {
      "nct_id": "NCT00527657",
      "title": "Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Neoplasms",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Lomustine",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Thalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2006-02-09",
      "completion_date": "2012-02-02",
      "has_results": false,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-06-10T18:26:38.729Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00527657"
    },
    {
      "nct_id": "NCT00003911",
      "title": "S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "stereotactic radiosurgery",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 2,
      "start_date": "1999-07",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2013-01-31",
      "last_synced_at": "2026-06-10T18:26:38.729Z",
      "location_count": 86,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003911"
    },
    {
      "nct_id": "NCT03175432",
      "title": "Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "BRAF V600 Wild Type",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Intracranial Melanoma",
        "Metastatic Malignant Neoplasm in the Brain",
        "Metastatic Melanoma",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Refractory Melanoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2017-06-15",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-06-10T18:26:38.729Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03175432"
    },
    {
      "nct_id": "NCT00003308",
      "title": "Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer",
        "Melanoma (Skin)",
        "Metastatic Cancer",
        "Ovarian Cancer",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "stereotactic radiosurgery",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "1999-02-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-06-10T18:26:38.729Z",
      "location_count": 11,
      "location_summary": "Des Moines, Iowa • Kalamazoo, Michigan • Papillion, Nebraska + 5 more",
      "locations": [
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        },
        {
          "city": "Papillion",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003308"
    },
    {
      "nct_id": "NCT05388877",
      "title": "E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Metastatic Malignant Neoplasm in the Brain",
        "Metastatic Malignant Neoplasm in the Central Nervous System",
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "MEK-1/MEKK-1 Inhibitor E6201",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2022-10-20",
      "completion_date": "2025-06-02",
      "has_results": false,
      "last_update_posted_date": "2025-08-19",
      "last_synced_at": "2026-06-10T18:26:38.729Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05388877"
    },
    {
      "nct_id": "NCT00072163",
      "title": "Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Melanoma",
        "Stage IV Melanoma",
        "Tumors Metastatic to Brain"
      ],
      "interventions": [
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "thalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2003-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-17",
      "last_synced_at": "2026-06-10T18:26:38.729Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00072163"
    },
    {
      "nct_id": "NCT00539383",
      "title": "A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors With and Without Brain Metastases"
      ],
      "interventions": [
        {
          "name": "ANG1005",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Angiochem Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2007-10",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2014-07-31",
      "last_synced_at": "2026-06-10T18:26:38.729Z",
      "location_count": 3,
      "location_summary": "Canton, Ohio • Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Canton",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00539383"
    },
    {
      "nct_id": "NCT04700072",
      "title": "Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab/Quavonlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 56,
      "start_date": "2021-05-03",
      "completion_date": "2025-10-17",
      "has_results": false,
      "last_update_posted_date": "2025-10-28",
      "last_synced_at": "2026-06-10T18:26:38.729Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Santa Monica, California • Aurora, Colorado + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04700072"
    },
    {
      "nct_id": "NCT01378975",
      "title": "A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Melanoma"
      ],
      "interventions": [
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 146,
      "start_date": "2011-07",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2025-06-25",
      "last_synced_at": "2026-06-10T18:26:38.729Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01378975"
    }
  ]
}